Articles Archive - Page 208 of 806

China Approves Use of Tocilizumab for Coronavirus Patients

Reuters Staff | March 4, 2020

BEIJING (Reuters)—China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe conditions, health authorities said on Wednesday, as the country seeks to build up treatment regimens to help the infected recover. Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients…

Epidemiology of Rheumatoid Arthritis May Be Changing

Will Boggs, MD | March 3, 2020

NEW YORK (Reuters Health)’Over the last three decades, there has been a significant decline in the incidence of rheumatoid factor (RF) positive rheumatoid arthritis (RA), while the overall incidence of RA has remained about the same, researchers report. “These trends may suggest changing serological profile of RA over time which may have implications for RA…

Phase 3 Results for Olokizumab in RA Patients

Michele B. Kaufman, PharmD, BCGP | March 3, 2020

In a recent study, olokizumab proved safe and effective for treating the signs and symptoms of RA and improving patients’ physical function…

How Autoimmune & Non-Autoimmune Family Conditions Predict Rheumatoid Arthritis

Carina Stanton | March 3, 2020

New research has incorporated confounders, such as smoking, to build a clearer picture of family-related factors that may help predict who will develop rheumatoid arthritis…

As Lyme Disease Spreads Across the U.S., Stay Alert for Fatal Lyme Carditis

Lara C. Pullen, PhD | March 3, 2020

The reach of Lyme disease is expanding across the U.S., and cases may be under-reported. A recent CDC case report describes the experiences of two patients with fatal cases of Lyme carditis…

A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis

Arthritis & Rheumatology | February 27, 2020

Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.